Disclosure Of Entity's Operating Segments [Text Block]

Innate Pharma - Filing #882171

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Disclosure of entity's operating segments [text block]	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	—	—	24 703 EUR	—	69 773 EUR	—
Tax expense (income)	—	—	— EUR	—	— EUR	—
Profit (loss) before tax	—	—	45 478 EUR	—	829,000 EUR	—
Profit (loss) from continuing operations	—	—	45 478 EUR	—	829,000 EUR	—
Profit (loss)	—	52 809 EUR	52 809 EUR	—	63 984 EUR	63 984 EUR
Assets	267 496 EUR	—	—	307 423 EUR	—	—
Cash flows from (used in) operating activities	—	—	58 457 EUR	—	51 767 EUR	—
Cash flows from (used in) investing activities	—	—	917,000 EUR	—	13 370 EUR	—
Cash flows from (used in) financing activities	—	—	26 818 EUR	—	1 177 EUR	—
Disclosure of products and services [text block]	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]